About the author
Medical University of Vienna, Vienna, Austria
Markus Raderer undertook his early medical studies at the Medical University of Vienna, completing his residency in internal medicine between 1993 and 1999, specialising in haematology and oncology in 2001. He received the venia docendi for ‘Applied and Experimental Oncology’ and ‘Internal Medicine’ in 1999 and 2002, respectively. Professor Raderer is currently the Programme Director for Extranodal Lymphomas and for Endocrine Tumours at the Medical University of Vienna. He has been responsible for the management and conduct of phase II and III clinical trials at his institution since 1992.
Professor Raderer is on the Editorial Board of a number of journals including the Journal of Clinical Oncology, World Journal of Gastroenterology, and Middle European Journal of Medical Oncology. He has participated on consensus panels for the European Gastrointestinal Lymphoma Study Group (EGILS) on the topic of B-cell lymphoma of mucosa-associated lymphoid tissue, and the European Society of Medical Oncology (ESMO) on the subject of the management of lymphoid malignancies.
For a list of publications see http://www.ncbi.nlm.nih.gov/pubmed/?term=raderer+m
Global Medical Discovery featured article: Long-term safety and activity of cladribine in patients with extranodal B-cell marginal zone lymphoma of the mucosa-associated lymphoid tissue (MALT) lymphoma